Mr. Alexander Krantz reports

ADVANCED PROTEOME ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING, ENTERS INTO INVESTOR RELATIONS AGREEMENT

Advanced Proteome Therapeutics Corp.'s 2014 annual general meeting of shareholders was held on Tuesday, July 22, 2014, at which meeting all resolutions were approved. The resolutions passed at the meeting include the following:

1. The number of directors for the ensuing year was set at three;
2. The following individuals were re-elected directors of the company: Alexander (Allen) Krantz, Jean M. Bellin and Gary W. Hayes;
3. Dale Matheson Carr-Hilton LaBonte LLP, chartered accountant, was reappointed as auditor of the company;
4. Adoption of the company's 10-per-cent rolling share option plan was ratified and approved;
5. Adoption of the company's advance notice policy was ratified and approved.

The board of directors appointed Mr. Krantz as president, chief executive officer and secretary, and Kenneth C. Phillippe as chief financial officer for the ensuing year.

Mr. Krantz, Mr. Bellin and Mr. Hayes were appointed members of the audit committee, of which Mr. Bellin is the chair.

The company also announces that it has retained Scott Young to provide investor relations services, and assist the company in fostering productive, continuing dialogues with analysts, brokers, investors or other financial professionals.

Mr. Young, who is based in Ontario, has spent the past 12 years working in the capital markets sector, inclusive of 10 years as vice-president of business development, corporate development and investor relations for biotechnology, technology and mining companies. He specializes in biotechnology and technology companies, assisting clients to communicate effectively to build an avid audience and develop strong relationships with potential investors. Besides his activities throughout Canada, Mr. Young has extensive contacts in Asia, Africa, Europe, North America and South America.

The investor relations agreement is for an initial period of 12 months, with an option to renew for a further term at the mutual agreement of both parties. In compensation, the company has granted Mr. Young an option to purchase 200,000 common shares, exercisable for a period of one year at an exercise price of 25 cents per share. The options are granted pursuant to the company's stock option plan, and will vest in accordance with the provisions therein and the policies of the TSX-V, which require that options granted to a consultant providing investor relations services must vest in stages over 12 months with no more than one-quarter of the options vesting in any three-month period. This will bring the total number of options outstanding under the stock option plan to 6.44 million, with 4,064,590 remaining available for grant.

The investor relations agreement is subject to approval by the TSX-V.

We seek Safe Harbor.